Oncogene addiction
When a cancer depends so completely on one mutated gene that blocking it collapses the tumour.
Coined by Weinstein (2002). EGFR, ALK, BCR-ABL, KIT, BRAF V600E tumours exemplify it: dramatic responses to single agents, followed by acquired resistance. Underlies the entire targeted-therapy paradigm.
Young adults with a grade 2 IDH-mutant glioma who have had surgery can now take a daily tablet that slows or reverses tumour growth and defers radiotherapy and chemotherapy, both of which carry long-term cognitive costs, by years. It confirms that the IDH mutation is a driver that can be targeted, not just a marker. Whether it improves survival or cognition over the long term, and whether it helps in higher-grade or previously treated tumours, is unknown.
Every resected non-squamous lung cancer should be tested for EGFR mutations, because patients who carry one live longer if they take osimertinib for three years after surgery. The trial does not tell us whether adjuvant chemotherapy can be omitted, nor what happens on relapse after osimertinib, and the three-year duration was chosen empirically.
For ALK-positive advanced lung cancer, lorlatinib as the first drug offers the possibility of many years without progression and strong protection against brain metastases. Alectinib and brigatinib remain alternatives with a gentler side-effect profile; the choice weighs lorlatinib's cognitive, metabolic and weight effects against its unmatched duration of control.
Anyone diagnosed with advanced lung cancer should have EGFR testing before treatment, because osimertinib as the first drug gives the longest disease control, protects the brain, and is well tolerated. Chemotherapy is not the first step for these patients. The remaining questions are whether to intensify upfront (adding chemotherapy or amivantamab) and how to treat resistance when it develops.
There are not thousands of cancer genes, and any one patient's tumour is driven by only a few of them. That makes targeted sequencing panels sensible, but because most drivers are lost tumour suppressors, drugs exist for only a minority, which is why the same group turned to early detection.
The hallmarks are the mental map most oncologists and researchers use to think about what cancer is and where drugs act. A newcomer can understand nearly every therapy as an attack on one hallmark: kinase inhibitors on proliferative signalling, checkpoint blockade on immune evasion, anti-VEGF drugs on angiogenesis.
Pages like this
not linked directly; found by shared links- TargetALK
Shares Driver mutation, University of Colorado Cancer Center, Crizotinib, Oncogene.
- ProductImatinib
Shares Bud Romine, Brian Druker, Tyrosine kinase inhibitor (TKI), Kinase.
- TermGene fusion
Shares Driver mutation (actionable / targetable alteration), University of Colorado Cancer Center, Crizotinib, CROWN: lorlatinib versus crizotinib as first treatment for ALK-positive lung cancer.
- TermGrowth signal
Shares Oncogene, Hallmark: sustaining proliferative signalling, Targeted therapy, Kinase.
- ProductOsimertinib
Shares West Japan Oncology Group, ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer, Guangdong Provincial People's Hospital, Tyrosine kinase inhibitor (TKI).
- PersonYi-Long Wu
Shares ADAURA: three years of osimertinib after surgery for EGFR-mutated lung cancer, Guangdong Provincial People's Hospital, International Association for the Study of Lung Cancer.
- TargetBRAF
Shares Driver mutation, Oncogene, Cancer genome landscapes: about 140 driver genes, and each tumour needs only a handful, Hallmark: sustaining proliferative signalling.
- PersonJanet Rowley
Shares Bud Romine, Brian Druker, Chronic myeloid leukaemia (CML).